SHP2/NAMPT-IN-1
SHP2/NAMPT-IN-1 is an orally active dual inhibitor of SHP2 and NAMPT, with IC50 values of 30.5 nM and 24.4 nM, respectively. SHP2/NAMPT-IN-1 reduces NAD+ levels and p-ERK expression by inhibiting NAMPT. SHP2/NAMPT-IN-1 can inhibit the migration and colony formation of MDA-MB-231 cells and promote apoptosis. SHP2/NAMPT-IN-1 has anti-proliferative activity against a variety of tumor cell lines and can reverse PD-L1-mediated T-cell immunosuppression. SHP2/NAMPT-IN-1 can be used for breast cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C24H26ClN7OS
- Masse moléculaire:496.03
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KYSE-520 cell line | IC50 |
0.6 μM
|
Exhibits antiproliferative activity against KYSE520 cells for 72 h.
Exhibits antiproliferative activity against KYSE520 cells for 72 h.
|
42324937 |
| HT-29 | IC50 |
1.4 μM
|
Exhibits antiproliferative activity against HT29 cells for 72 h.
Exhibits antiproliferative activity against HT29 cells for 72 h.
|
42324937 |
| MDA-MB-231 | IC50 |
0.34 μM
|
Exhibits antiproliferative activity against MDA‑MB‑231 cells for 72 h.
Exhibits antiproliferative activity against MDA‑MB‑231 cells for 72 h.
|
42324937 |
| HepG2 | IC50 |
2.9 μM
|
Exhibits antiproliferative activity against HepG2 cells for 72 h.
Exhibits antiproliferative activity against HepG2 cells for 72 h.
|
42324937 |
| HeLa | IC50 |
1.4 μM
|
Exhibits antiproliferative activity against HeLa cells for 72 h.
Exhibits antiproliferative activity against HeLa cells for 72 h.
|
42324937 |
| A549 | IC50 |
0.7 μM
|
Exhibits antiproliferative activity against A549 cells for 72 h.
Exhibits antiproliferative activity against A549 cells for 72 h.
|
42324937 |
| MCF7 | IC50 |
1.3 μM
|
Exhibits antiproliferative activity against MCF‑7 cells for 72 h.
Exhibits antiproliferative activity against MCF‑7 cells for 72 h.
|
42324937 |
| 4T1 | IC50 |
0.7 μM
|
Exhibits antiproliferative activity against 4T1 cells for 72 h.
Exhibits antiproliferative activity against 4T1 cells for 72 h.
|
42324937 |
In Vitro
SHP2/NAMPT-IN-1 (Compound A4) exhibits potent inhibitory activity against SHP2 and NAMPT in cell-free enzyme assays (IC50 = 30.5 nM and 24.4 nM, respectively), while showing no significant inhibition against SHP1, PTP1B, and NMNAT (IC50 > 20 μM) [1].
SHP2/NAMPT-IN-1 (72 h) exhibits antiproliferative activity against multiple SHP099‑insensitive tumor cell lines, including KYSE520 (IC50 = 0.6 μM), HT29 (IC50 = 1.4 μM), MDA‑MB‑231 (IC50 = 0.34 μM), HepG2 (IC50 = 2.9 μM), HeLa (IC50 = 1.4 μM), A549 (IC50 = 0.7 μM), as well as breast cancer cells MCF‑7 (IC50 = 1.3 μM) and 4T1 (IC50 = 0.7 μM) [1].
SHP2/NAMPT-IN-1 (1 μM; 1 h) significantly enhances the thermal stability of SHP2 and NAMPT proteins in MDA‑MB‑231 cells in cellular thermal shift assay (CETSA), indicating that it binds to the target proteins[1].
SHP2/NAMPT-IN-1 (0.5-2 μM; 24 h) dose‑dependently reduces phosphorylated ERK (p‑ERK) levels in MDA‑MB‑231 cells[1].
SHP2/NAMPT-IN-1 (0.25-1 μM; 24 h) dose‑dependently reduces intracellular NAD⁺ levels in MDA‑MB‑231 cells[1].
SHP2/NAMPT-IN-1 (0.5-2 μM; 12 days) significantly inhibits colony formation in MDA‑MB‑231 cells[1].
SHP2/NAMPT-IN-1 (0.5-2 μM; 24 h) induces apoptosis in MDA‑MB‑231 cells, with apoptosis rates of 31.6% and 38.9%, respectively[1].
SHP2/NAMPT-IN-1 (0.5-2 μM; 24 h) upregulates the pro‑apoptotic protein Bax and downregulates the anti‑apoptotic protein Bcl‑2 in MDA‑MB‑231 cells[1].
SHP2/NAMPT-IN-1 (0.5-2 μM; 24-48 h) significantly inhibits cell migration in wound healing and Transwell migration assays in MDA‑MB‑231 cells[1].
SHP2/NAMPT-IN-1 (0.25-1 μM; 72 h) dose‑dependently reverses PD‑L1‑mediated immunosuppression and promotes IFN‑γ and IL‑2 secretion in Jurkat T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 1, 2 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced the levels of phosphorylated ERK (p-ERK).
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:24 h
-
Result:Upregulated the pro-apoptotic protein Bax and downregulated the anti-apoptotic protein Bcl-2.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:12 days
-
Result:Significantly inhibited colony formation, showing superior efficacy over the combination of FK866 and SHP099.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis with rates of 31.6% (at 0.5 μM) and 38.9% (at 2 μM), higher than the FK866/SHP099 combination (22.7%).
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:24 and 48 h
-
Result:Significantly delayed wound closure and inhibited cell migration.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0.5, 2 μM
-
Incubation Time:48 h
-
Result:Significantly inhibited cell migration, with superior efficacy over FK866 or SHP099 alone.
-
Cell Line:Jurkat cells
-
Concentration:0.25, 0.5, 1 μM
-
Incubation Time:72 h
-
Result:Dose‑dependently reverses PD‑L1‑mediated immunosuppression and promotes IFN‑γ and IL‑2 secretion in Jurkat T cells.
Parmacokinetics
In Vivo
SHP2/NAMPT-IN-1 (10 mg/kg; orally; once daily; for 15 days) suppresses tumor growth and significantly increases CD8+ cytotoxic T-cell infiltration in tumor tissues in a 4T1 syngeneic immunocompetent BALB/c mouse model, and the combination with anti-PD-1 antibody (HY-P99144) significantly enhances the TGI[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (6-8 weeks old) or immunocompetent female BALB/c mice were inoculated subcutaneously in the right flank with 5 × 105 MDA-MB-231[1].
-
Dosage:This compound (5, 10, 20 mg/kg); FK866 (HY-50876) (10 mg/kg); SHP099 (HY-100388) (20 mg/kg); FK866 + SHP099 (10 + 20 mg/kg)
-
Administration:This compound and SHP099: Oral gavage (p.o.); FK866: Intraperitoneal injection (i.p.); once daily (q.d.) for 15 days
-
Result:Dose-dependently suppressed tumor growth with TGI values of 38% (5 mg/kg), 50% (10 mg/kg), and 68% (20 mg/kg), surpassing the efficacy of FK866 (TGI = 19%), SHP099 (TGI = 24%), and the FK866 + SHP099 combination (TGI = 35%).
No significant body weight loss was observed in any treatment group throughout the dosing period.
H&E staining of excised tumor tissues revealed nuclear retraction and reduced tumor cellularity.
H&E staining of major organs (heart, liver, spleen, lung, kidney) showed no significant histological changes between the control and experimental groups, indicating favorable biosafety.
-
Animal Model:Female BALB/c nude mice (6-8 weeks old) or immunocompetent female BALB/c mice were inoculated subcutaneously in the right flank with 5 × 105 4T1 cells.[1]
-
Dosage:This compound (10 mg/kg); anti-PD-1 antibody ((HY-P99144)) (5 mg/kg); This compound + anti-PD-1 antibody (10 + 5 mg/kg)
-
Administration:This compound: Oral gavage (p.o.), once daily (q.d.) for 15 days; anti-PD-1 antibody: Intraperitoneal injection (i.p.), biweekly (BIW) for 15 days
-
Result:Monotherapy suppressed tumor growth with a TGI of 39%, comparable to anti-PD-1 antibody monotherapy (TGI = 40%).
The combination of this compound and anti-PD-1 antibody exhibited superior antitumor efficacy with a TGI of 71%, significantly greater than either monotherapy.
Immunohistochemistry (IHC) staining of tumor tissues revealed a marked increase in CD8⁺ cytotoxic T-cell infiltration in the monotherapy and combination groups, indicating the induction of in vivo antitumor immunity and synergy with PD-1 blockade.
No significant body weight loss was observed in any group.
Chemical Information
-
Masse moléculaire 496.03
-
Formule C24H26ClN7OS
-
SMILES
NC(CC1)(C)CCN1C(C=N2)=NC(N)=C2SC3=CC=CC(NC(/C=C/C4=CN=CC=C4)=O)=C3Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- SHP2/NAMPT-IN-1
- SHP2
- NAMPT
- Apoptosis
- ERK
- Oral activity
- KYSE520
- MDA-MB-231
- HT29
- HepG2
- HeLa
- A549
- MCF-7
- 4T1
- Jurkat
- MDA-MB-231 xenograft model in BALB/c nude mice
- 4T1 syngeneic model in immunocompetent BALB/c mice
- esophageal cancer
- triple-negative breast cancer
- breast cancer
- colon cancer
- hepatocellular carcinoma
- cervical cancer
- non-small cell lung cancer
- Inhibitor
- inhibitor
- inhibit